Last updated: May 26, 2026
What is Cetrotide (cetrorelix) and what clinical-trial signals matter for 2025–2035?
Cetrotide is a gonadotropin-releasing hormone (GnRH) antagonist used to prevent premature luteinizing hormone (LH) surges in controlled ovarian stimulation. Commercial relevance is tied to assisted reproductive technology (ART) cycle volume, payer and clinic adoption of GnRH antagonists versus agonists, and ongoing supply stability in EU/US markets.
Core product positioning
- Indication: Prevention of premature LH surge during controlled ovarian stimulation for IVF/ICSI (label terms vary by jurisdiction).
- Drug class: GnRH antagonist.
- Competitive set: Other GnRH antagonists used in ART, primarily cetrorelix (Cetrotide) and ganirelix (and, in some geographies, alternative brands and generics).
Clinical-trial updates that typically drive near-term demand
- Comparative studies versus other GnRH antagonists on outcomes like ongoing pregnancy/live birth rates, OHSS incidence, cycle cancellation, and safety profiles.
- Pharmacokinetic (PK) and formulation work that supports interchangeability between presentations (powder + diluent vs ready-to-use formats, where applicable) and may affect substitution in tender/contracting.
- Real-world evidence updates from fertility networks that quantify uptake by protocol (fixed vs flexible dosing) and patient risk stratification (OHSS risk).
What can be forecasted from trial dynamics
- If trials and real-world datasets show stable or superior OHSS reduction with similar efficacy, adoption generally remains protocol-driven and tends to be resilient to new entrants.
- If trial signals emerge around simplified dosing or reduced clinic administration burden, procurement decisions can shift toward products with lower handling and lower wastage.
What clinical trials has Cetrotide completed, and which updates are likely to change labeling or uptake?
A full, decision-grade “clinical trials update” requires linking specific NCT/CT numbers to endpoints, enrollment status, topline results, and any protocol amendments that could support label expansion or new dosing claims. No such trial inventory and results set is available in the current request context, so a complete and accurate update cannot be produced.
How big is the Cetrotide market today, and what demand drivers move revenue?
A reliable market analysis for Cetrotide requires:
- current annual revenue by geography (EU, UK, US if applicable),
- volume estimates by ART cycle count and proportion using GnRH antagonists,
- market share versus ganirelix and any approved cetrorelix generics/biosimilars (no biosimilars; likely generics and follow-on brands),
- payer pricing trends and tender outcomes.
That data is not present in the request context, so a complete and accurate market sizing and share forecast cannot be produced.
What is the projected growth rate for Cetrotide based on ART cycle trends and GnRH-antagonist adoption?
A projection that is decision-grade depends on:
- forecast of IVF/ICSI cycle volumes by country/region,
- growth in clinically indicated ART uptake,
- risk management protocols shifting from GnRH agonist “long protocols” to GnRH antagonist “flexible/fixed protocols,”
- regulatory and supply events affecting availability.
No ART cycle forecasts by region and no current adoption baseline are provided. A complete and accurate growth projection cannot be produced.
When does Cetrotide lose exclusivity, and what are the likely generic entry windows?
A true exclusivity and generic entry timing analysis requires:
- Orange Book (if US product exists in that format) or EU SPC data,
- patent-by-patent expiration schedules for substance, composition, and method-of-use,
- pediatric data exclusivity or regulatory exclusivity overlays where applicable,
- history of Paragraph IV filings (US) if any.
This is not provided in the request context. A complete and accurate exclusivity timeline cannot be produced.
What patents protect cetrorelix products like Cetrotide, and how strong is the patent estate?
A defensible patent-strength assessment requires:
- specific patent numbers, assignees, jurisdictions,
- claim scope mapping to dosing regimens, formulations, and manufacturing,
- litigation or settlement records.
No patent estate details are included in the request context, so a complete and accurate patent landscape cannot be produced.
How many formulations and strengths are protected for Cetrotide, and what matters for substitution?
Substitution risk hinges on whether generics can rely on:
- pharmaceutical equivalence by strength and dosage form,
- bioequivalence demonstrated for the same formulation type,
- manufacturing process differences that could raise “non-infringement” defenses or block approval via listed patents.
Without a formulation list, strengths, and patent coverage specifics, a complete protection-by-formulation map cannot be produced.
What is the Orange Book status of Cetrotide, and what generic entry risks exist?
Orange Book status requires direct listing data: application numbers, listed patents, approval dates, and paragraph IV or consent decree history. None of that is present in the request context, so a complete and accurate Orange Book status summary cannot be produced.
Which companies market cetrorelix (including generics), and how does Cetrotide compare on pricing and contracting?
A market-competition comparison requires:
- brand and generic manufacturers by market,
- tender/contract pricing and rebate structures,
- availability, lead times, and any supply constraints.
No manufacturer list or pricing evidence is provided in the request context. A complete and accurate competitor and pricing comparison cannot be produced.
What patent litigation affects Cetrotide, and are there settlements that change entry timing?
A decision-grade litigation and settlement section requires:
- case captions and docket data,
- asserted patents and outcomes (dismissals, injunctions, modified claims),
- settlement dates and “effective entry” provisions.
No litigation records are available in the request context, so a complete and accurate litigation impact cannot be produced.
How do cetrorelix and ganirelix compare in efficacy, safety, and protocol adoption?
A rigorous clinical comparison requires head-to-head trials or consistent meta-analyses with endpoint definitions and protocol comparability. This cannot be completed without trial citation data and study selection evidence, which are not present in the request context.
What FDA and EMA regulatory milestones affect Cetrotide supply and lifecycle?
A regulator-milestone analysis requires:
- marketing authorization dates,
- renewal timelines,
- variations affecting manufacturing sites,
- signal reviews tied to safety communications.
No EMA/FDA lifecycle details are included in the request context, so the milestone analysis cannot be completed.
Key Takeaways
- A decision-grade clinical-trials update, market analysis, and exclusivity-based projection for Cetrotide cannot be produced from the information provided in the request context.
- To deliver actionable timelines, market sizing, and entry-risk windows, a complete dataset is required covering (i) trial registry and results, (ii) regional revenue and volume data, and (iii) jurisdiction-specific exclusivity and patent listings.
FAQs
- What ART protocol trends drive GnRH antagonist uptake and how do they affect cetrorelix brands?
- What endpoints in cetrorelix trials best predict OHSS risk reduction and cycle cancellation?
- How do generic cetrorelix substitution and tender contracts typically work in EU fertility centers?
- What regulatory exclusivities (SPC/pediatric/market exclusivity) most often delay generic entry for fertility injectables?
- Which manufacturing-site changes most commonly trigger supply interruptions for injectable ART drugs?
References
No sources were provided or available in the request context.
